dr. (Saskia) S. Knies

All publications (14)

• Article (13)

  • M.M. Versteegh, S. Knies & W.B.F. Brouwer (2016). From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. Pharmacoeconomics (Print), 34 (11), 1071-1074. doi: http://dx.doi.org/10.1007/s40273-016-0431-y[go to publisher's site]
  • O. Mandrik, S. Knies, Z. Kalo & J.L. Severens (2015). REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. International Journal of Technology Assessment in Health Care, 31 (6), 434-441. doi: http://dx.doi.org/10.1017/S0266462315000677[go to publisher's site]
  • O. Mandrik, I. Corro Ramos, S. Knies, M.J. Al & J.L. Severens (2015). Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research (online), 2015 (7), 279-289. doi: 10.2147/CMAR.S79258[go to publisher's site]
  • O. Mandrik, S. Knies & J.L. Severens (2015). Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan. ClinicoEconomics and Outcome Research, 7, 347-356. doi: http://dx.doi.org/10.2147/CEOR.S79513[go to publisher's site]
  • O. Mandrik, S. Knies, O. Golubovska, O. Duda, L. Dudar, S. Fedorchenko, O. Zaliska & J.L. Severens (2015). Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. Open medicine, 10 (1), 25-33. doi: http://dx.doi.org/10.1515/med-2015-0006[go to publisher's site]
  • S. Knies, A. Boonen & J.L. Severens (2014). Do the Washington Panel recommendations hold for Europe: inversigating the relation between quality of life versus work-status, absenteeism and presenteeism. BioMed Central, 12 (24). doi: http://dx.doi.org/10.1186/1478-7547-12-24[go to publisher's site]
  • S. Knies, A. Boonen, M.J.J.M. Candel, S.M.A.A. Evers & J.L. Severens (2013). Compensation Mechanisms for Lost Productivity: A Comparison between Four European Countries. Value in Health, 16, 740-744. doi: http://dx.doi.org/10.1016/j.jval.2013.03.1624[go to publisher's site]
  • S. Knies, G. Lombardi, M. Commers, H. Dauben, S.M.A.A. Evers, K. Michelsen, W. Oortwijn, C. Opara & H. Brand (2013). Supporting decision making in cross-border regions: a health technology assessment tool for hospitals. International Journal of Technology Assessment in Health Care, 29 (1), 71-78. doi: 10.1017/S0266462312000785
  • S. Knies, M.J.J.M. Candel, A. Boonen, S.M.A.A. Evers, A.J.H.A. Ament & J.L. Severens (2012). Lost Productivity in Four European Countries among Patients with Rheumatic Disorders. Pharmacoeconomics (Print), 30 (9), 795-807. doi: http://dx.doi.org/10.2165/11591520-000000000-00000
  • S. Knies, J.L. Severens, A.J.H.A. Ament & S.M.A.A. Evers (2010). The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines. Value in Health, 13 (5), 519-527.
  • S. Knies, M.J.J.M. Candel, A. Boonen, S.M.A.A. Evers, A.J.H.A. Ament & J.L. Severens (2010). Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable? Pharmacoeconomics (Print), 30 (9), 795-807.
  • S. Knies, A.J.H.A. Ament, S.M.A.A. Evers & J.L. Severens (2009). The transferability of economic evaluations. Testing the model of Welte. Value in Health, 12 (5), 730-738.
  • S. Knies, S.M.A.A. Evers, M.J.J.M. Candel, J.L. Severens & A.J.H.A. Ament (2009). Utilities of the EQ-5D: transferable or not? Pharmacoeconomics (Print), 27 (9), 767-779.

• Supervised Theses (1)

  • O. Mandrik. Is transferability an issue? Use of economic studies in Ukraine and other central and eastern European countries. EUR Prom./coprom.: prof.dr. J.L. Severens, O. Zalis'ka & dr. S. Knies.

Present position